BACKGROUND: Sevelamer, a non-calcium containing phosphate binder often used in end-stage renal disease, is frequently associated with gastrointestinal side effects. However, whether Sevelamer is also a risk factor for peritonitis in patients on peritoneal dialysis (PD) is unclear. METHODS: We performed a retrospective analysis of all patients treated with peritoneal dialysis (n = 48) between June 2003 and December 2009 at our institution. Data consisted of 1200 patient months and 49 episodes of peritonitis. Patient demographic data, comorbidities, concomitant medication, laboratory parameters, and microbiology results were obtained from the medical records and from the hospital's electronic database. RESULTS: The mean peritonitis incidence rate was to 0.50/patient year. An identified risk factor for peritonitis was time on PD. Neither Sevelamer use in general nor the mean daily intake was associated with the risk for peritonitis even after adjustment. CONCLUSION: Treatment with Sevelamer is not associated with a higher risk for peritonitis.
BACKGROUND: Sevelamer, a non-calcium containing phosphate binder often used in end-stage renal disease, is frequently associated with gastrointestinal side effects. However, whether Sevelamer is also a risk factor for peritonitis in patients on peritoneal dialysis (PD) is unclear. METHODS: We performed a retrospective analysis of all patients treated with peritoneal dialysis (n = 48) between June 2003 and December 2009 at our institution. Data consisted of 1200 patient months and 49 episodes of peritonitis. Patient demographic data, comorbidities, concomitant medication, laboratory parameters, and microbiology results were obtained from the medical records and from the hospital's electronic database. RESULTS: The mean peritonitis incidence rate was to 0.50/patient year. An identified risk factor for peritonitis was time on PD. Neither Sevelamer use in general nor the mean daily intake was associated with the risk for peritonitis even after adjustment. CONCLUSION: Treatment with Sevelamer is not associated with a higher risk for peritonitis.
Authors: Konstantinos P Katopodis; Emilios K Andrikos; Chariklia D Gouva; Eleni T Bairaktari; Petros M Nikolopoulos; Lamprini K Takouli; Christos S Tzallas; Moses S Elisaf; Michael V Pappas; Kostas C Siamopoulos Journal: Perit Dial Int Date: 2006 May-Jun Impact factor: 1.756
Authors: Wai Kei Lo; Suk Wai Cheng; Suk Yi Ng; Terence Pok-Siu Yip; Man Fai Lam; Kai Chung Tse; Sing Leung Lui Journal: Perit Dial Int Date: 2008 Jan-Feb Impact factor: 1.756
Authors: Serdar Kahvecioglu; Ibrahim Akdag; Murat Kiyici; Mustafa Gullulu; Mahmut Yavuz; Alparslan Ersoy; Kamil Dilek; Mustafa Yurtkuran Journal: J Nephrol Date: 2005 Jan-Feb Impact factor: 3.902
Authors: Alexander S Goldfarb-Rumyantzev; Arsalan N Habib; Bradley C Baird; Lev L Barenbaum; Alfred K Cheung Journal: Am J Kidney Dis Date: 2007-11 Impact factor: 8.860
Authors: Despina Kotsanas; Kevan R Polkinghorne; Tony M Korman; Robert C Atkins; Fiona Brown Journal: Nephrology (Carlton) Date: 2007-06 Impact factor: 2.506
Authors: Julia Kerschbaum; Andreas Vychytil; Karl Lhotta; Friedrich C Prischl; Martin Wiesholzer; Veronika Machhold-Fabrizii; Gertrude Kopriva-Altfahrt; Christoph Schwarz; Peter Balcke; Rainer Oberbauer; Reinhard Kramar; Paul König; Michael Rudnicki Journal: PLoS One Date: 2013-07-02 Impact factor: 3.240